News
INCY
95.12
-2.58%
-2.52
Bank of America Securities Remains a Buy on Incyte (INCY)
TipRanks · 1d ago
Wells Fargo Remains a Hold on Incyte (INCY)
TipRanks · 2d ago
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Pacific Edge Limited (OtherPFGTF) and Mach7 Technologies (OtherTDMMF)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Dyne Therapeutics (DYN)
TipRanks · 3d ago
Incyte frontMIND Phase 3 study backs tafasitamab filing in first-line DLBCL
PUBT · 3d ago
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
Barchart · 3d ago
Weekly Report: what happened at INCY last week (0504-0508)?
Weekly Report · 4d ago
Impressive Earnings May Not Tell The Whole Story For Incyte (NASDAQ:INCY)
Simply Wall St · 5d ago
Assessing Incyte (INCY) Valuation After FDA Wins For Jakafi XR Opzelura And Pancreatic Cancer Therapy
Simply Wall St · 05/08 17:48
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
Seeking Alpha · 05/08 17:25
Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
TipRanks · 05/08 16:34
Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
TipRanks · 05/07 19:58
Incyte Reports Phase 3 TRuE-AD4 Week 24 Data Showing Opzelura Cream Maintained High Rates Of Disease Control And Symptom Relief In Adults With Moderate Atopic Dermatitis At EADV 2026
Benzinga · 05/07 12:53
Incyte says Opzelura cream sustains disease control through 24 weeks in Phase 3 TRuE-AD4 trial
PUBT · 05/07 12:50
INCYTE - OPZELURA WELL TOLERATED WITH 1.7% APPLICATION SITE REACTIONS AND NO NEW SAFETY SIGNALS UP TO 24 WEEKS
Reuters · 05/07 12:50
The Bull Case For Incyte (INCY) Could Change Following FDA Approval Of Once-Daily Jakafi XR
Simply Wall St · 05/07 11:50
Incyte grants new CFO equity awards including 38,429 stock options at $97.14
PUBT · 05/06 21:08
Mirum Q1 FY26 operating loss widens to $789.47 million; revenue rises 43.3% to $159.88 million
PUBT · 05/06 20:06
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 05/06 15:30
Jakafi XR Approval Tests Incyte Valuation As Growth Outlook Softens
Simply Wall St · 05/06 07:38
More
Webull provides a variety of real-time INCY stock news. You can receive the latest news about Incyte Corp through multiple platforms. This information may help you make smarter investment decisions.
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.